Private equity firms engaged in an unusual bidding battle this year: slugging it out over an upmarket chain of private hospitals in China.
TPG and a consortium that included Shanghai Fosun Pharmaceutical, emerged the victor in the fight for US-listed Chindex International after sweetening its bid and shelling out $461m. Chinese media and people close to the deal named Carlyle as the rival bidder, although it declined to comment.
Chindex is the top of the pyramid of hundreds of potential private hospital deals, as investors chase a Chinese gold rush.
您已閱讀16%（553字），剩餘84%（2845字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。